Studies suggested that SGLT-2 inhibitors are associated with significantly improved cardiovascular outcomes in patients with type 2 diabetes (T2DM) (8), including improving myocardial structure (9) and cardiac function (10), inhibition of cardiac inflammation (10), reduction of oxidative stress (11) and myocardial cell apoptosis (10), protection of mitochondrial function (9) and maintaining ion balance in isolated cardiomyocytes (12). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.